ACTUATE THERAPEUTICS INC. - COMMON STOCK

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 ديسمبر 2024 08:28:17 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

17 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to be Added to Russell 2000® Index

26 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

12 نوفمبر 2024 08:00:03 بحسب Nasdaq GlobeNewswire

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

29 أكتوبر 2024 18:39:24 بحسب Nasdaq GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

23 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

16 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

11 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05 سبتمبر 2024 09:10:56 بحسب Nasdaq GlobeNewswire

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

20 أغسطس 2024 09:00:00 بحسب Nasdaq GlobeNewswire